PT3341015T - Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária - Google Patents

Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária

Info

Publication number
PT3341015T
PT3341015T PT16840215T PT16840215T PT3341015T PT 3341015 T PT3341015 T PT 3341015T PT 16840215 T PT16840215 T PT 16840215T PT 16840215 T PT16840215 T PT 16840215T PT 3341015 T PT3341015 T PT 3341015T
Authority
PT
Portugal
Prior art keywords
blockade
targeted cells
immune costimulatory
enhanced depletion
costimulatory agonist
Prior art date
Application number
PT16840215T
Other languages
English (en)
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58100930&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3341015(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of PT3341015T publication Critical patent/PT3341015T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
PT16840215T 2015-08-26 2016-08-26 Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária PT3341015T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210279P 2015-08-26 2015-08-26

Publications (1)

Publication Number Publication Date
PT3341015T true PT3341015T (pt) 2021-10-12

Family

ID=58100930

Family Applications (1)

Application Number Title Priority Date Filing Date
PT16840215T PT3341015T (pt) 2015-08-26 2016-08-26 Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária

Country Status (11)

Country Link
US (3) US10894831B2 (pt)
EP (1) EP3341015B2 (pt)
JP (3) JP7198083B2 (pt)
AU (2) AU2016310348B2 (pt)
CA (1) CA2996167A1 (pt)
ES (1) ES2894335T3 (pt)
HK (1) HK1257824A1 (pt)
PL (1) PL3341015T5 (pt)
PT (1) PT3341015T (pt)
SI (1) SI3341015T2 (pt)
WO (1) WO2017035480A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6460796B2 (ja) * 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
US10550187B2 (en) * 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
PT3341015T (pt) * 2015-08-26 2021-10-12 Univ Leland Stanford Junior Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3592387A4 (en) 2017-03-09 2021-03-31 The Board of Trustees of the Leland Stanford Junior University TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING THE CD47 SIGNAL PATH
EP3697817B1 (en) 2017-10-18 2022-10-05 Forty Seven, Inc. Anti-cd47 agent-based ovarian cancer therapy
CA3094098A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies unique to d47, pd-l1 and their uses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002425A2 (en) 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
CA2785139A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
KR20110085038A (ko) 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
HUE060541T2 (hu) 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
JP6460796B2 (ja) 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
AU2013359167B2 (en) 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
AU2015204766B2 (en) * 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
CN106535914B (zh) 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-α变体构建体及其用途
FI3186395T4 (fi) * 2014-08-26 2023-05-25 Kantasolujen siirto kantasoluihin kohdistuvan aineen ja immunoregulatorisen signaloinnin modulaation yhdistelmällä
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
PE20180778A1 (es) 2015-08-07 2018-05-07 Alexo Therapeutics Inc Construcciones con un dominio sirp-alfa o sus variantes
PT3341015T (pt) * 2015-08-26 2021-10-12 Univ Leland Stanford Junior Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária
CN108367073A (zh) * 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症

Also Published As

Publication number Publication date
PL3341015T5 (pl) 2024-04-08
AU2016310348A1 (en) 2018-03-15
US20230257464A1 (en) 2023-08-17
SI3341015T1 (sl) 2021-11-30
WO2017035480A1 (en) 2017-03-02
AU2016310348B2 (en) 2023-01-05
US11608377B2 (en) 2023-03-21
JP2018525421A (ja) 2018-09-06
JP7198083B2 (ja) 2022-12-28
SI3341015T2 (sl) 2024-03-29
JP2023126368A (ja) 2023-09-07
EP3341015B2 (en) 2023-12-27
CA2996167A1 (en) 2017-03-02
JP2021138756A (ja) 2021-09-16
ES2894335T3 (es) 2022-02-14
EP3341015B1 (en) 2021-07-28
US20200223923A1 (en) 2020-07-16
HK1257824A1 (zh) 2019-11-01
US10894831B2 (en) 2021-01-19
JP7313398B2 (ja) 2023-07-24
AU2023201987A1 (en) 2023-05-04
PL3341015T3 (pl) 2021-12-13
US20210095034A1 (en) 2021-04-01
EP3341015A1 (en) 2018-07-04
EP3341015A4 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
HK1257824A1 (zh) 用cd47阻斷劑和免疫共刺激激動劑增强靶細胞的消耗
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1250236A1 (zh) 用gdf8抑制劑增加力量和功能的方法
ZA201801048B (en) Encoderless motor with improved granularity and methods of use
HK1256417A1 (zh) 氰基噻吩並***並二氮雜環庚三烯及其用途
IL254412B (en) Prostate antigen standard and its uses
GB2534557B (en) Methods and resources for creating permissions
IL259202A (en) Modified immune cells and their use
HK1256368A1 (zh) 加利車黴素-抗體-藥物綴合物和使用方法
HK1258850A1 (zh) 抗tpbg抗體及使用方法
EP3370764A4 (en) CELLS MARKED BY LIPID CONJUGATES AND METHODS OF USING THE SAME